A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

► One dose of cell-culture-derived, pandemic influenza vaccine adequate for adults. ► Two doses required for the elderly. Adjuvanted vaccine well tolerated in all subjects. ► Rapid production by cell-culture helps to meet global demand for pandemic vaccines.